Immunohistochemical characterisation and localisation of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and the effects of unilateral vestibular deafferentation

被引:24
|
作者
Ashton, JC [1 ]
Zheng, YW [1 ]
Liu, P [1 ]
Darlington, CL [1 ]
Smith, PF [1 ]
机构
[1] Univ Otago, Sch Med, Dept Pharmacol & Toxicol, Sch Med Sci, Dunedin, New Zealand
关键词
CB1; receptor; unilateral vestibular deafferentation; vestibular nucleus complex;
D O I
10.1016/j.brainres.2004.06.065
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
CB1 receptor expression has been reported to be low in the brainstem compared with the forebrain, and low in the vestibular nucleus complex (VNC) compared with other regions in the brainstem. However, a frequent effect of cannabis is dizziness and loss of balance. This may be due to the activation of cannabinoid receptors in the central vestibular pathways. We used immunohistochemistry to study the distribution of CB1 receptor protein in the VNC, and Western blotting to measure CB 1 receptor expression in the VNC following unilateral vestibular deafferentation (UVD); the hippocampal CA1, CA2/3 and dentate gyrus (DG) regions were also analysed for comparison. This study confirms a previous electrophysiological demonstration that CB1 receptors exist in significant densities in the VNC and are likely to contribute to the neurochemical control of the vestibular reflexes. Nonetheless, CB1 receptor expression did not change significantly in the VNC during vestibular compensation. In addition, despite some small but significant changes in CB1 receptor expression in the CA2/3 and the DG following UVD, in no case were these differences statistically significant in comparison to both control groups. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:264 / 271
页数:8
相关论文
共 43 条
  • [31] Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat
    Walsh, Sinead
    Mnich, Katarzyna
    Mackie, Ken
    Gorman, Adrienne M.
    Finn, David P.
    Dowd, Eilis
    BRAIN RESEARCH BULLETIN, 2010, 81 (06) : 543 - 548
  • [32] Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens
    Sperlagh, Beata
    Windisch, Katalin
    Ando, Romeo D.
    Vizi, E. Sylvester
    NEUROCHEMISTRY INTERNATIONAL, 2009, 54 (07) : 452 - 457
  • [33] The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus
    Thiemann, Gunnar
    Di Marzo, Vincenzo
    Molleman, Areles
    Hasenoehrl, Ruediger U.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 89 (03) : 384 - 391
  • [34] Sub-chronic administration of AM251, CB1 receptor antagonist, within the nucleus accumbens induced sensitization to morphine in the rat
    Haghparast, Abbas
    Azizi, Pegah
    Hassanpour-Ezatti, Majid
    Khorrami, Hossein
    Naderi, Nima
    NEUROSCIENCE LETTERS, 2009, 467 (01) : 43 - 47
  • [35] Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice
    Irwin, Nigel
    Hunter, Kerry
    Frizzell, Nonna
    Flatt, Peter R.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 581 (1-2) : 226 - 233
  • [36] Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB1 receptor density in cell membranes: an alternative to radioligand binding methods
    Saumell-Esnaola, Miquel
    Elejaga-Jimeno, Ainhoa
    Echeazarra, Leyre
    Borrega-Roman, Leire
    Barrondo, Sergio
    Lopez de Jesus, Maider
    Gonzalez-Burguera, Imanol
    Gomez-Caballero, Alberto
    Goicolea, Maria Aranzazu
    Salles, Joan
    Garcia del Cano, Gontzal
    MICROBIAL CELL FACTORIES, 2022, 21 (01)
  • [37] Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1/CB2 versus GPR55 receptors
    Wang, Xiao-Fei
    Galaj, Ewa
    Bi, Guo-Hua
    Zhang, Cindy
    He, Yi
    Zhan, Jia
    Bauman, Michael H.
    Gardner, Eliot L.
    Xi, Zheng-Xiong
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (08) : 1865 - 1880
  • [38] Capsazepine, a Transient Receptor Potential Vanilloid Type 1 (TRPV1) Antagonist, Attenuates Antinociceptive Effect of CB1 Receptor agonist, WIN55,212-2, in the Rat Nucleus Cuneiformis
    Parvishan, Asghar
    Taslimi, Zahra
    Ebrahimzadeh, Mohammad
    Haghparast, Abbas
    BASIC AND CLINICAL NEUROSCIENCE, 2011, 2 (04) : 19 - 26
  • [39] Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys
    Madsen, Morten V.
    Peacock, Linda
    Werge, Thomas
    Andersen, Maibritt B.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2006, 20 (05) : 622 - 628
  • [40] Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats
    Azizi, Pegah
    Haghparast, Abbas
    Hassanpour-Ezatti, Majid
    BEHAVIOURAL BRAIN RESEARCH, 2009, 197 (01) : 119 - 124